Cytomegalovirus (CMV) infection occurs very often after solid organ transplantation and is often a lifethreatening complication oflong-term immunosoppressive therapy. Actually it is unknown which type of drug is indicated to control the infection in immunocompromised patients. We studied 10 consecutive patients who had undergone heart-transplantation and in which CMV infection was the commonest posttransplant infectious disease. Our results suggest a careful monitoring of IgG seropositivity in heart transplant patients, especially when it is not possible to know the serum status of the donor.
Primary human Cytomegalovirus (CMV) infection is followed by persistence of the virus in a latent form. During life, CMV can reactivate, resulting in renewed shedding or development of the disease. CMV can interfere with the host immune control, but finally, the infection is controlled by the host's immune response. So CMV disease is restricted to the immunocompromised or immunologically immature host (children, transplant recipients and human immunodeficiency virus-infected patients) (1-2). Recurrent CMV disease has been reported to occur in 6% to 59% of solid-organ transplant recipients and typically occurs I-4 months after solid-organ transplantation (3) . In the immunocompromised patients, establishing the diagnosis ofCMV infection can still be difficult. CMV antigenemia assay and CMV-DNA detection by Polymerase Chain Reaction (PCR) or direct hybrid capture are able to detect and monitor the disease but have raised the question of the implications of asymptomatic viremia (4, 5) . The decision of how to treat the infection depends mainly on the immune status of the host. The most commonly used drugs are ganciclovir, foscarnet, cidofovir, valganciglovir, valaciclovir. Treatment of clinical disease is with a 2 to 3-week course of intravenous ganciclovir, which is effective in more than 90% of individuals (6-7). However, relapsing disease, particularly in those with primary infection, is an increasing problem, sometimes with the development of ganciclovir-resistant infection (8) . In order to prevent relapse, more prolonged oral courses of antiviral therapy, are being added to standard treatment.
A wide variety of prophylactic strategies have been evaluated in heart and other solid-organ transplant recipients, including antiviral agents, globulin preparations, combinations of these therapies, and pre-emptive treatment strategies based on early detection or identification of highrisk subset of patients. Many regimens have demonstrated efficacy in certain groups of patients, but a consensus has not been established yet in terms of a single preferable strategy (9) . This report summarizes the prevalence and way of onset of the CMV infection in the post-hearttransplantation period and the influence on the outcome of the transplantation at the "SS Annunziata" Hospital in Chieti, Italy.
MATERIALS AND METHODS
Between January 2001 and May 2003, 10 patients (8 males, 2 females, mean age 49 years), were subjected to bicaval orthotopic heart transplantation at the Heart Surgery Division of the "SS Annunziata" Hospital of Chieti, Italy, and followed up in the Clinics of Cardiology and Infectious Diseases at the same hospital. All the patients were studied for blood chemistry tests, viroimmunological techniques for the research of infectious processes (such as Epstein Barr virus, Herpes virus J-2, Toxoplasma gondii, HCV and HBV, HIV and CMV) including PCR, bacteriological tests, analyses of cultures performed on various biological fluids (blood, urine, pleuric liquid), on venous and urinary catheters, thoracic drainage tubes, epicardic and surgical wounds and by means of radiological diagnostic techniques.
RESULTS
Four patients (40 %) were affected with primary dilatative cardiomyopathy, 5 (50%) with postinfarct dilatative cardiomyopathy and I (l 0%) with inoperable angiosarcoma.
In the pre-transplant period all patients were positive for IgG-CMV (l 00%), 2 patients (20%) were positive for IgG anti-epstein-Barr virus, IgG-positive for Herpes simplex-I were detected in 2 patients (20%) and IgG for Toxoplasma gondii in 3 patients (30%). These 3 patients underwent preventive treatment with Trimethoprimsulfametoxazole. The donor's serum levels for Toxoplasma infection were identified in only one patient (D+/R-) and so preventive post-transplantation therapy was carried out for one month with pirimetaminesulphametopirazine. Regarding all the other infections, it was impossible to know the results of the donors' serum tests. The immune-suppressor drugs used were cyclosporin, azatioprine and steroids in all the patients except one in whom azatioprine was replaced by mophetile microphenolate for raised transaminase levels.
Tab. I. Characteristics of the patients of our study at the pre-transplantation screening. 
Tab. II. Main infections occurring in the heart transplant patients of our study. Seven patients (cases 3, 4, 5, 6, 7, 8 and 9) became CMV DNA positive and CMV antigenemiapositive (values between 1-2 cells1200000 PMN via quantitative PCR) a month after the operation without evident localization in an organ or specific symptoms of infections, except for case 7, in whom the infection reappeared with typical features in the oral mucosa. In this case we searched for CMV infection every week. All patients underwent preventive treatment with ganciclovir, resulting in negative values for serum antigen and CMV DN A. Case 4 became positive again for CMV with serum antigen positivity 3 months after concluding the therapy with ganciclovir, so that a second cycle of preventi ve treatment had to be performed, which restored negative values. It should be noted that an endomyocardic biopsy carried out during the CMV re-infection showed cardiac involvement from CMV in the absence of rejection. The results of subsequent biopsies were always negative. The patient underwent two skin biopsies because of the appearance of nodular lesions which were identified as "early Kaposi sarcoma lesions". No treatment was performed because the lesions remained stable and no visceral involvement was present.
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Cases 5 and 6 presented herpes-type lesions of the pharynx 10 days after transplantation, but these disappeared with oral administration of acyclovir. The main infections occurring in the heart transplant patients are shown in Tab. II.
DISCUSSION
In the transplantation of organs, the only effective treatment for terminal pathologies of various vital organs, one of the main causes of disease and mortality is infection, whose pathogenesis depends on numerous conventional and opportunist agents (10) (11) .
Besides the high doses of immune-suppressors, infective complications are also essentially linked to a number of other factors shown in Tab. III.
In our patients no apparently serious infections were observed. An occurrence of particular interest was the onset in one subject of an "early Kaposi sarcoma lesion" of the skin. In almost all the heart-transplant patients, a reactivation of a pre-existing endogenous CMV infection was observed which was probably due to the immune-suppressive therapy used. This infection was rarely symptomatic thanks to prompt preventive treatment with ganciclovir, which was started as soon as a positive result for CMV viremia or positive antigen titers were obtained, irrespective of quantitative levels.
We screened for IgG/lgM and performed PCR testing for CMV each week during the first month and every two weeks after until the sixth month. Although our data are limited, we suggest careful monitoring ofIgG seropositivity, especially when the serum status of the donor is unknown. Our clinical practice is in accordance with standard guidelines and similar clinical protocols for limiting CMV infections in heart transplant patients (12) . CMV infections remain the most significant determinants of transplant outcome, because they are the most common life-threatening complications of long-term immunosoppressive therapy.
